Coronary Flow Velocity Reserve is Improved by PPAR-α Agonist Fenofibrate in Patients with Hypertriglyceridemia

Cardiovascular Therapeutics

Volumn 31, Issue 3, 2013, Pages 161-167

  Wang, Guang ^a   He, Liyun ^a   Liu, Jinbo ^a   Yu, Jie ^a   Feng, Xinheng ^a   Li, Fuwang ^b   Hao, Yanting ^a   Mao, Jieming ^a   Hong, Tianpei ^a   Chen, Alex F ^c   Wang, Xian ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Coronary flow velocity reserve; Endothelial function; Homocysteine; PPAR

Indexed keywords

FENOFIBRATE; HOMOCYSTEINE;

ADULT; ARTERIAL STIFFNESS; ARTICLE; CONTROLLED STUDY; CORONARY FLOW RESERVE; DOPPLER ECHOCARDIOGRAPHY; ENDOTHELIUM; FEMALE; FOLLOW UP; HUMAN; HYPEREMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE WAVE; QUANTITATIVE ANALYSIS; REST; TREATMENT DURATION;

ADULT; AGED; BLOOD FLOW VELOCITY; CHEMOKINE CCL2; CORONARY CIRCULATION; FEMALE; FENOFIBRATE; HOMOCYSTEINE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PPAR ALPHA;

EID: 84876672006     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00307.x     Document Type: Article

References (30)

1. Hattori Y, Hottori S, Wang X, Satoh H, Nakanishi N, Kasai K. Oral administration of tetrahydrobipterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 2007;27:865-870.
2. Barbier O, Pineda Torra I, Duguay Y, Blanquart C, Fruchart J, Glineur C, Staels B. Pleiotropic action of peroxisome proliferator-activated receptors in lipid metabolism and atheroslcerosis. Arterioscler Thromb Vasc Biol 2002;22:717-726.
3. Gervois P, Kleemann R, Pilon A, Koenig W, Staels B, Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after in vivo chronic treatment with the peroxisome proliferator-activated receptor αactivator fenofibrate. J Biol Chem 2004;279:16154-16160.
4. Kowalski J, Okopien B, Madej A, Zielinski M, Belowski D, Kalina Z, Herman ZS. Effects of fenofibrate and simvastatin on plasma sICAM and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther 2003;41:241-247.
5. Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2004;24:658-663.
6. Yakubu MA, Nsaif RH, Oyekan AO. Peroxisome proliferator-activated receptor α activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture. J Pharmacol Exper Therapeut 2007;320:774-781.
7. Capell WH, DeSouza CA, Poirier P, et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003;23:307-313.
8. Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery folw-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002;90:1254-1257.
9. He L, Zeng H, Li F, et al. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobipterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab 2010;299:E1061-E1065.
10. Wang G, Wei J, Guan Y, Mao J, Wang X. PPAR-γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 2005;54:590-597.
11. Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. PPAR-γ agonist improved arterial stiffness in type 2 diabetes patients with coronary artery disease. Metabolism 2007;56:1396-1401.
12. Yu J, Zhang Z, Li Z, et al. PPARγ agonist improve coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 2010;38:86-94.
13. Hozumi T, Yoshida K, Ogata Y, Akasaka T, Asami Y, Takagi T, Morioka S. Noninvasive assessment of significant left anterior coronary descending artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998;97:1557-1562.
14. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-126.
15. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein -1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-2534.
16. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001;357:905-910.
17. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 2008;82:884-891.
18. Li P, Shibata R, Maruyama S, Kondo M, Ohashi K, Ouchi N, Murohara T. Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway. Am J Physiol Endocrinol Metab 2010;299:E560-E566.
19. Hennuyer N, Tailleux A, Torpier G, Mezdour H, JC Fruchart, Staels B, Fiévet C. PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1897-1902.
20. Campisis R, Di Carli MF. Assessment of coronary flow reserve and microcirculation: a critical perspective. J Nucl Cardiol 2004;11:3-11.
21. Aoun S, Blacher J, Safar ME, Mourad JJ. Diabetes mellitus and renal failure: Effects on large artery stiffness. J Hum Hypertens 2001;15:693-700.
22. Fukuda D, Yoshiyama M, Shimada K, et al. Relation between aortic stiffness and coronary flow reserve in patients with coronary artery disease. Heart 2006;92:759-762.
23. Ryan K, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007;194:e123-130.
24. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet 2005;366:1849-1861.
25. Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001;50:3-11.
26. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006;91:1770-1778.
27. Jin L, Caldwel RB, Li-Masters T, Caldwell RW. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol 2007;58:191-206.
28. Topal G, Brunet A, Millamvoye E, Boucher JL, Rendu F, Devynck MA, David-Dufilho M. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 2004;36:1532-1541.
29. Wang G, Dai J, Mao J, Zeng X, Yang X, Wang X. Folic acid reverses hyper-responsiveness of LPS-induced chemokine secretion from monocytes in patients with hyperhomocysteinemia. Atherosclerosis 2005;179:395-402.
30. Dai J, Li W, Chang L, et al. Role of redox factor-1 in hyperhomocysteinemia-accelerated atherosclerosis. Free Radic Biol Med 2006;41:1566-1577.